Purdue University’s Bindley Bioscience Center is working with India-based Eyestem Research Private Ltd. to develop cellular platforms for COVID-19 research. Purdue says the agreement allows its investigators to use Eyestem’s cell culture system as part of its anti-COVID screening platform to research the characteristics of the SARS-CoV-2 virus.
Purdue says the collaboration could ultimately result in testing potential drugs being developed at Purdue.
“Finding ways to treat this novel coronavirus in order to minimize illness and death is a global imperative, so it is critical to create cross-border collaborations that can accelerate the pace of science,” said Ramaswamy Subramanian, Bindley’s director. “We are hoping that by working with this Indian startup, we can identify new drug screening strategies, which will be the fastest way out of the current crisis.”
Purdue says Bindley will supply the cells to the Purdue investigators.
You can learn more about the partnership’s research by clicking here.